CytomX Therapeutics (CTMX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.41, +8.07% vs the prior close of $2.23.
- Volume 2.99M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CTMX jumps 8.1% to $2.41. Closed at $2.41, +8.07% vs the prior close of $2.23. Day range $2.25–$2.43, opened at $2.26.
CTMX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CTMX jumps 8.1% to $2.41
- Closed at $2.41, +8.07% vs the prior close of $2.23. Day range $2.25–$2.43, opened at $2.26.
- Volume was 2.99M shares, 0.9x its 50-day average of 3.46M.
- Price is -21.3% vs its 50-day average ($3.06) and -39.4% vs its 200-day average ($3.98).
- 52-week range $2.20–$8.21; today's close sits at 3% of that range, 70.6% below the 52-week high.
Oct 14, 2026 — CTMX slides 4.1% to $2.23, a 52-week low, 3 down days in a row
- Closed at $2.23, -4.09% vs the prior close of $2.33. Day range $2.20–$2.35, opened at $2.30.
- Volume was 3.35M shares, 1.0x its 50-day average of 3.45M.
- Price is -27.6% vs its 50-day average ($3.08) and -44.1% vs its 200-day average ($3.99).
- 52-week range $2.20–$8.21; today's close sits at 0% of that range, 72.8% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CTMX slides 3.9% to $2.33, a 52-week low
- Closed at $2.33, -3.93% vs the prior close of $2.42. Day range $2.32–$2.45, opened at $2.45.
- Volume was 5.22M shares, 1.5x its 50-day average of 3.42M.
- Price is -25.1% vs its 50-day average ($3.10) and -41.8% vs its 200-day average ($4.00).
- 52-week range $2.32–$8.21; today's close sits at 0% of that range, 71.7% below the 52-week high.
Oct 12, 2026 — CTMX slides 5.8% to $2.42, a 52-week low
- Closed at $2.42, -5.84% vs the prior close of $2.57. Day range $2.41–$2.58, opened at $2.56.
- Volume was 4.00M shares, 1.2x its 50-day average of 3.41M.
- Price is -22.4% vs its 50-day average ($3.12) and -39.6% vs its 200-day average ($4.01).
- 52-week range $2.41–$8.21; today's close sits at 0% of that range, 70.5% below the 52-week high.
Oct 9, 2026 — CTMX jumps 4.0% to $2.57
- Closed at $2.57, +4.05% vs the prior close of $2.47. Day range $2.44–$2.58, opened at $2.46.
- Volume was 3.04M shares, 0.9x its 50-day average of 3.38M.
- Price is -18.0% vs its 50-day average ($3.13) and -36.0% vs its 200-day average ($4.02).
- 52-week range $2.43–$8.21; today's close sits at 2% of that range, 68.7% below the 52-week high.
Oct 8, 2026 — CTMX slides 3.1% to $2.47, a 52-week low, 3 down days in a row
- Closed at $2.47, -3.14% vs the prior close of $2.55. Day range $2.43–$2.55, opened at $2.51.
- Volume was 4.50M shares, 1.4x its 50-day average of 3.32M.
- Price is -21.5% vs its 50-day average ($3.15) and -38.6% vs its 200-day average ($4.02).
- 52-week range $2.43–$8.21; today's close sits at 1% of that range, 69.9% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — CTMX dips 0.4% to $2.55, a 52-week low
- Closed at $2.55, -0.39% vs the prior close of $2.56. Day range $2.52–$2.65, opened at $2.53.
- Volume was 2.34M shares, 0.7x its 50-day average of 3.31M.
- Price is -19.3% vs its 50-day average ($3.16) and -36.8% vs its 200-day average ($4.03).
- 52-week range $2.48–$8.21; today's close sits at 1% of that range, 68.9% below the 52-week high.
Oct 6, 2026 — CTMX dips 0.8% to $2.56
- Closed at $2.56, -0.78% vs the prior close of $2.58. Day range $2.51–$2.63, opened at $2.61.
- Volume was 1.96M shares, 0.6x its 50-day average of 3.32M — lighter than usual.
- Price is -19.4% vs its 50-day average ($3.17) and -36.6% vs its 200-day average ($4.04).
- 52-week range $2.48–$8.21; today's close sits at 1% of that range, 68.8% below the 52-week high.
Oct 5, 2026 — CTMX rises 0.8% to $2.58
- Closed at $2.58, +0.78% vs the prior close of $2.56. Day range $2.48–$2.67, opened at $2.55.
- Volume was 1.77M shares, 0.5x its 50-day average of 3.32M — lighter than usual.
- Price is -19.1% vs its 50-day average ($3.19) and -36.2% vs its 200-day average ($4.05).
- 52-week range $2.48–$8.21; today's close sits at 2% of that range, 68.6% below the 52-week high.
Oct 2, 2026 — CTMX dips 2.7% to $2.56, a 52-week low, 3 down days in a row
- Closed at $2.56, -2.66% vs the prior close of $2.63. Day range $2.55–$2.68, opened at $2.68.
- Volume was 2.62M shares, 0.8x its 50-day average of 3.29M.
- Price is -20.0% vs its 50-day average ($3.20) and -36.9% vs its 200-day average ($4.05).
- 52-week range $2.55–$8.21; today's close sits at 0% of that range, 68.8% below the 52-week high.
- That makes 3 straight losses.
CTMX latest news & SEC filings
Every SEC filing by or about CTMX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.42M (prior year $18.66M) (-92.4% vs Jun 30, 2025)
- Net income: -$20.67M (prior year -$154.00K) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 5, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 3, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 30, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CTMX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 16, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.89% (largest 8.1%).
- Liquidity: about 3.79M shares (≈$9.13M) trade per day on average.
- 52-week position: $2.41 vs a range of $2.20–$8.21 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 6 sales; latest: Christopher Ogden sold 1,624 shares on Jun 15, 2026.
- Latest filings: 8-K Aug 6, 2026; 10-Q Aug 6, 2026; 8-K Jul 27, 2026.
- Share count: 217.90M shares outstanding (Jul 31, 2026), +32.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CTMX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.26 | 2.43 | 2.25 | 2.41 | 2.99M |
| Oct 14, 2026 | 2.30 | 2.35 | 2.20 | 2.23 | 3.35M |
| Oct 13, 2026 | 2.45 | 2.45 | 2.32 | 2.33 | 5.22M |
| Oct 12, 2026 | 2.56 | 2.58 | 2.41 | 2.42 | 4.00M |
| Oct 9, 2026 | 2.46 | 2.58 | 2.44 | 2.57 | 3.04M |
| Oct 8, 2026 | 2.51 | 2.55 | 2.43 | 2.47 | 4.50M |
| Oct 7, 2026 | 2.53 | 2.65 | 2.52 | 2.55 | 2.34M |
| Oct 6, 2026 | 2.61 | 2.63 | 2.51 | 2.56 | 1.96M |
| Oct 5, 2026 | 2.55 | 2.67 | 2.48 | 2.58 | 1.77M |
| Oct 2, 2026 | 2.68 | 2.68 | 2.55 | 2.56 | 2.62M |
| Oct 1, 2026 | 2.71 | 2.78 | 2.62 | 2.63 | 2.70M |
| Sep 30, 2026 | 2.78 | 2.80 | 2.70 | 2.72 | 3.22M |
| Sep 29, 2026 | 2.70 | 2.83 | 2.65 | 2.75 | 4.46M |
| Sep 28, 2026 | 2.68 | 2.76 | 2.60 | 2.69 | 2.69M |
| Sep 25, 2026 | 2.74 | 2.78 | 2.66 | 2.70 | 3.03M |
| Sep 24, 2026 | 2.75 | 2.78 | 2.68 | 2.75 | 3.08M |
| Sep 23, 2026 | 2.90 | 2.91 | 2.67 | 2.78 | 4.96M |
| Sep 22, 2026 | 2.86 | 2.99 | 2.76 | 2.94 | 7.92M |
| Sep 21, 2026 | 2.80 | 2.83 | 2.74 | 2.76 | 2.33M |
| Sep 18, 2026 | 2.83 | 2.86 | 2.72 | 2.76 | 9.60M |
About CytomX Therapeutics
CytomX Therapeutics (CTMX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1501989.
CTMX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Alan Ashworth | Director | Jun 22, 2026 |
| Charles S. Fuchs | Director | Jul 30, 2026 |
| Halley E Gilbert | Director | Jun 22, 2026 |
| Elaine V Jones | Director | Jun 22, 2026 |
| Sean A. Mccarthy | CEO | Mar 19, 2026 |
| James R Meyers | Director | Jun 22, 2026 |
| Mani Mohindru | Director | Jun 22, 2026 |
| Zhen Su | Director | Jun 22, 2026 |
| Matthew P. Young | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Marcia Belvin | SVP, Chief Scientific Officer | Mar 19, 2026 |
| Alejandra Carvajal | Chief Legal Officer | Aug 5, 2026 |
| Yu-Waye Chu | Chief Medical Officer | Mar 19, 2026 |
| Rachael Lester | Chief Business Officer | Feb 4, 2026 |
| Sean A. Mccarthy | CEO | Mar 19, 2026 |
| Christopher Ogden | Chief Financial Officer | Jun 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 15, 2026 | Christopher Ogden | Sale | 1,624 | $3.05 |
| Mar 17, 2026 | Yu-Waye Chu | Sale | 21,279 | $6.42 |
| Mar 17, 2026 | Marcia Belvin | Sale | 31,492 | $6.42 |
| Mar 17, 2026 | Sean A. Mccarthy | Sale | 118,969 | $6.42 |
| Mar 17, 2026 | Christopher Ogden | Sale | 19,323 | $6.42 |
| Nov 6, 2025 | Sean A. Mccarthy | Sale | 101,793 | $4.54 |
CTMX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $76.20M | $-17.37M | — | $-75.59M |
| Dec 31, 2024 | $138.10M | $31.87M | — | $-86.23M |
| Dec 31, 2023 | $101.21M | $-569.00K | — | $-56.03M |
| Dec 31, 2022 | $53.16M | $-99.32M | — | $-110.79M |
| Dec 31, 2021 | $37.31M | $-115.87M | — | $-119.03M |
Latest balance sheet: total assets $381.23M, total liabilities $79.16M, cash $17.22M (as of Jun 30, 2026).
CTMX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $3.37 |
| May 7, 2026 | 8-K Item 2.02 (results) | $4.00 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $6.75 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $4.19 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $2.10 |
| May 12, 2025 | 8-K Item 2.02 (results) | $2.13 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $0.62 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $1.00 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 11, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CTMX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.